joining across by you plan our that start XXXX press XXXX we I'll fourth for full release with are corporate results the call. and quarter the priorities. proxy requirements, NASDAQ discussing today. objectives review will and Thank our X then including all progress, Listing I year our our filing comply to XXXX
and closing turning provide who remarks, Before Chief I and financial our over open financial answers. Sprague, results provide then Financial John we'll will call our call the to Officer; and our XXXX. questions for review outlook will the for
at a [Technical NASDAQ with Panel, we with and Qualifications million we participated Listed of $XX regain the reminder, requirement. XX of period least consecutive Difficulty] received a Market to plan letter that Hearing we with of days. had MVLS or Today, million for a As Listing detailed the comply us compliance we in meeting a the business $XX MVLS presented Securities NASDAQ to a from XXXX, failed informing Value
from response the coming NASDAQ a expect We in weeks.
stockholders, approved included which Servicing lender, shares shares XX,XXX CRG the today Preferred the of steps, LLC Our which Convertible conversion Series our by XXX,XXX includes previously CRG NASDAQ compliance by was common occurred B of Biosystems' or and following plan held stock. Stock TX of into
which of term a be X, April allow Biosystems' is to proxy loan occurring held TX includes meeting nearly XX, at up its special seeking or preliminary CRG the filing into approval stockholders XXXX, to Step on of convert also XX% to $XX million common stock. today, of to a
this within of expect to We issuance and portion of loan days the the of the XX common meeting. occur term stock cancellation of the
NASDAQ interest which business plan, Additionally, stockholders, will of and best it catalysts can discuss securities. market key access numerous potential value our company our maintaining listed broadens attract mergers and create for and NASDAQ of we our capital to listing the increase part compliance while stockholders we employees, our both the liquidity helps have the in our as company of is believe for better that shortly, maintains and and not we We retain the acquisitions. believe value positions
interest company's we payment is Another burden benefit are thus of future lowering reducing expenses. plan and the that our debt
XXXX our I'll our discuss to enhancing priorities: across and X Now progress shift gears advancing pipeline. operations our our XXXX our and corporate our sales, accelerating objectives
corporate our first priority. our Accelerating with Starting sales.
health XXX,XXX U.S. who care and an each another die Sepsis death an reminder, hospitals continues Americans costing year. to the our hospice billion human a $XX plus #X the Sepsis cause in As of in the XX,XXX U.S. exact annually, claiming system enormous estimated is of economic toll. annually. Sepsis cause hospitalization of #X is lives
survivors, within Sepsis XX be to XX% days hospital the cause causing Finally, XX% within U.S. and is #X readmission, of days. sepsis XX XX-day rehospitalized of
only targeted antimicrobial FDA-cleared of by a products to hour X has the blood up sepsis-causing increases X% X without directly in detect days of TX positive is for to to the risk each need to mortality from hours detection wait pathogens able for sepsis-causing delayed pathogens Rapid Biosystems as blood critical treatment. culture.
million In and full X record TX including Panel revenue including and we product international $X.X XXXX, our Instruments total approaching Biosystems U.S. to is installed in year sales base, We achieved XX instruments of market. growing the XX the revenue $X.X million, of TXBacteria team market. in now U.S. achieved the in TXDx globally, which markets added XXX
million, $X.X of quarter and quarter compared growth fourth to the XX% the quarter. sepsis accelerated product and revenue XXXX, sales each of we related In representing of achieved the of third sequential month
expand increasing into installed selling test test by new in existing customers more TXDx by distribution XXXX, international customers, existing continuing revenue. panel U.S. countries. selling to to our objectives international include our Looking Instruments We and base panel revenue new the to in network products of our by plan increase and expanding geographies to and forward markets to
TXCandida TXDx products the we TXLyme Panel, customers XXXX, to with the indication, or on existing instrument, each opportunity attract an TXBiothreat and X FDA-cleared Panel, During represents pediatric expect TXBacteria test to run increase and the expanded commercialize believe among We these the customers. of utilization the new to tests new a Panel including Panel. which panels test
customers The expanded are most Panel identify. feedback to include Acinetobacter to on of was which baumannii, bacteria developed detection using important TXBacteria the from direct species
of found drive test increased nearly now this platform the as adoption bacterial panel bloodstream sepsis-causing of in expanded latest FDA to expect infections. pathogens We all XX% covers clearance our commonly
testing essential Panel to believe improve FDA-cleared antimicrobial faster Panel and detection for it the as patients. We're an outcomes. segment patients our the use of expanded infected our a targeted to pediatric outcome drive new to clinical therapy appropriate expand of achieving include a pediatric positive their on cost treatment is market TXCandida We getting our to and TXCandida increased platform opens testing. will pediatric allow antifungal to FDA include adoption will clinicians for reduce claim by of submission outcomes on expecting pathogens pediatric these improving the and Rapid
XXXX, BARDA, we to the or government focus TXBiothreat FDA our collaboration clearance shifted of which September the with developed commercialization. Following Panel U.S. in in the we
exposure the ongoing bioterrorism. to East, wars Europe the provides the TXBiothreat biothreat risk and it Given sensitivity Panel is and Health U.S. increased including The other Stockpile, Middle multiple believe in population targets of in Response the global we and opportunities unique Public allies. Laboratory Strategic unparalleled to State Network, Or specificity, for agencies, National international the offers government U.S. an Labs, creating sales, government
we're sell products version the through capitalize partners the developed Given TXLyme is with our on potential a XXXX. of to we opportunity. advances what of network exploring laboratory a we we commercialize our Panel a to Panel, intend TXLyme Accordingly, Internationally, in believe test significant distributors.
distribution expansion continued XXXX, international During network. we expect our of
that into through Netherlands, market the Vietnam, one and distribution and have existing we've reentered Today, we our Belgium expanded the of we distributors. announced in Switzerland
evidence. direct our diagnostic expanding the for As part growth the commercial TX from collaboration pneumonia. NIH-funded our technology detection Leadership Group, Resistance evaluate with We we our announced strategy, of blood to recently ventilator-assisted of Biosystems or Antibacterial prioritized clinical ARLG
FDA-cleared currently study antimicrobial providing strengthen The we TXResistance combined to a improve by Specifically, observational, Panel aid ability the missed therapy, Panel an conventional detect for in diagnostic outcomes, forward methods targeted feasibility can provide the more available. update testing study. to the whether TXBacteria evaluated and and stewardship once in blood look will exploring in and infections will be the prospective, diagnostic
detection performance or and Difficulty] by TXMR. of TXResistance in TX management. products genes presented whole for data by of benefits presented poster presentations demonstrating encouraging accuracy also showing technology and Panel. IDWeek patient from rapid speed, antibiotic Resonance At TX [Technical Oral were October, TXDx blood clinical direct included of team Real-world customers. our Biosystems new data, poster The clinical Magnetic early XXXX panels highlighted instrument resistance the and part samples were as detection the sepsis sepsis data
in of the economic to benefits of and technology. continue clinical We increasing our our support, appreciate customer both awareness aiding
enhancing raw to Throughout significant Moving priority, we backorder. progress This addressing operations enhancing issues, the material test processes leadership, manufacturing and XXXX, strengthening our operations. our improving made corporate sepsis mitigating second panel included our our operations.
XXXX. I'm announce cleared Panel we cleared back the pleased back in orders Panel December in January TXCandida and the Panel all and to for XXXX, the for orders we TXResistance all that TXBacteria
count operating of loan the or XX, reduced permanently $X covenant XX%, the December and made expense cash We reducing minimum During balance $XX term period material head approximately and to sheet date our from we XXXX, million reductions. XXXX, by interest-only and our by our debt million maturity $XXX,XXX. strengthened extended to
balance Looking our forward strengthen of [Technical approval or nearly sheet Difficulty] stockholder TX loan following million Biosystems to our of with CRG term earlier, $XX version XXXX XX% into equity.
scrap, improve cutover. reduce our to inventory our sheet, expect margins, and product improve and continue efficiency to and delivery ERP of complete we to the to balance addition, panels In test Oracle sepsis TXDx increase positively levels Instruments on-time impact system reduce gross
areas: proprietary across share new pipeline, need and sepsis, detection treatment. focused expanding TXDx Reminder, we which our to menu the and blood our Moving disease, pipeline. made technology rapid-pathogen our the X are direct is a our from third advancements significant on instrument. which to Lyme FDA-cleared test We've all applying on for critical targeted-antimicrobial product priority, bioterrorism
FDA During XXXX, received clearances. FDA and X have XXX(k) we we already X filed submissions
premarket Panel. FDA XXXX. And receipt First, we TXBiothreat the of we XXX(k) a the September FDA submitted notification to announced XXX(k) for in clearance
if runs from a glanders, diagnostic including threats As tests Difficulty] pathogens the organisms biothreat mortality detect typhus. not promptly simultaneously tularemia, is have FDA-cleared CDC blood, TXDx a been as These XX%. TXBiothreat that molecular on melioidosis treated direct XX% X Panel and rates and cause that by Instrument to [Technical anthrax, the reminder, pathogens, have identified can of the
XX.X% Panel agreement all or of targets, except X was which XXX% of percent specificity for clinical and XXX%. Francisella or positive for demonstrated TXBiothreat the agreement tularensis, demonstrated negative Our all percent of evaluation sensitivity targets
submitted include Acinetobacter clearance TXBacteria premarket announced expanded the to of detection this FDA to week. Second, XXX(k) receipt a we FDA the baumannii. we of XXX(k) earlier And for notification Panel
to without detect bacterial The baumannii, need a Panel pneumonia, culture. aeruginosa, test pathogens in blood days pathogens wait for hours commonly including approximately XX% a E. is only diagnostic to Panel sepsis-causing Difficulty] in blood to able FDA-cleared As directly [Technical aureus, all TXBacteria just Staph E.coli. bacterial infections expanded sepsis-causing bloodstream found covers faecium, X the Acinetobacter X TXBacteria the Pseudomonas now from positive reminder, of the
to nosocomial approaches. carbapenems, large Acinetobacter and common important Acinetobacter prevention antibiotics, Acinetobacter antimicrobial rate identified to therapeutic baumannii, improved has a Acinetobacter bloodstream XX%. the treatment. pan-antibiotic-resistant the resistance has infections, targeted many the of bacteria detection mortality World rapid including Due was most and a requires critically the Organization importance highlights and baumannii XX% study emergence of the crude of that pathogen baumannii In most Health of to as tenth ICU
the December to XXX(k) XXXX, include testing. expand of premarket FDA-cleared use pediatric in the to Third, the to FDA we notification submitted TXCandida a Panel
the detected TXCandida morbidity the to blood in from without to of able to glabrata. U.S. FDA-cleared hospital and stay the albicans, to the in reminder, Panel to According culture. species hours to including U.S. Centers a by only $XX,XXX the costs candida for days of a candida XX a with CDC, detect Care significant directly up just to are children TXCandida present diagnostic X parapsilosis, pathogens again, causing Candida blood Control tropicalis, caused are positive in Candida length test increased contributor wait a Health Disease As burden of Candida X is and need Panel, Candida the sepsis days System all candidiasis. estimated invasive a species for children U.S. infections XX% for or with by and candida Prevention and the in mean the excess X an invasive Candida hospital and major mortality hospitalized krusei Candida
XXXX XXX.X A than that that at the Rome, compared pediatric received of TXCandida hours Microbiology Italy, Clinical fungal culture. suspected patients Bambino blood (sic) found tested of conducted results ] Mycology Hospital Panel infections Journal Gesu were with faster in Species Identification [ bloodstream to study
we forward in our expect to Looking XXXX, continued pipeline. advances
to on Following panels, testing, utility expand Panel the include test use pediatric to of FDA of clinical of expand pediatric part commitment expect XXX(k) our our clearance to TXCandida receive my comments testing. the the sepsis to as we
We also TXBacteria expand testing. premarket Panel notification FDA-cleared use plan to submit the pediatric of to the to FDA the a XXX(k)
FDA the X Candida Panel, X is for Panel these auris upon in our TXLyme panels addition, our have test. breakthrough pipeline, FDA-cleared prioritized Instrument, U.S. TXDx new run or Each on received these In of which test a we and provide submission. the will to new of device including TXResistance FDA previously the designed designation, review and tests test each
antibiotic-resistant infections molecular The to detect known resistance days X is blood the to XX need simultaneously TXResistance test direct culture. from genes to for designed cause just a wait a hours without antibiotic Panel positive to blood diagnostic in X
the menu antimicrobial test that our the adoption important resistance drive of to will believe first a culture platform. expect We our independent be Panel it expanding TXResistance direct from very as or increased addition can test be we to blood
We the Panel U.S. all TXResistance have trial. external clinical in completed testing
internal in we XXX(k) XXXX. now are quarter We to a stability notification focused the to and and life premarket of third submit testing, on expect shelf the FDA
vector-borne be leading as after infection. weeks can current the a The for test accurately direct With disease a a disease the test diagnostic in in TXLyme diagnostics. an a new cases relies the Panel critical to algorithm Difficulty] annually, to only molecular antibody disease major developed designed Lyme that's in diagnostic antibodies the from far detect bacteria and Lyme burgdorferi, of XXX,XXX test need There's is Lyme is for disease diagnostic the X-tiered stand-alone estimated presence America. X originally blood disease The on U.S. process X of by surveillance Borrelia cause XXXX used [Technical
critical. If much eradicate. untreated, harder debilitating disease Early diagnosis body spread of and left become to disease Lyme the can is throughout
detection earlier the Panel As winner of and to receive Diagnostic Accelerator, Innovation been Services as Prize, we and U.S. help for Alexandra LymeX Lyme of we've II selected and or $XXX,XXX early development the Steven support will Health Foundation. Department announced of month, Phase this & a from our accelerate Human the TXLyme Lyme We Cohen LymeX the the appreciate the disease. the from in
grant-based earlier, laboratory advance to we're and mentioned in funding LDT. test partners, commercialization advancing as potential TXLyme As obtain with TXLyme we're discussion I to launch initial Panel and U.S. or non-dilutive Panel. plan the the the laboratory toward We're potential exploring the developed a
rate health up associated CDC costs with the high as by to on as $XX as fungal global Organization. CDC fungal early by help are Health serious test of Candida the for threat treatment. blood the of of just The the mortality to of auris days species test fungal blood Candida to in a a detect lead hours designed Candida a is X direct believe diagnostic Candida without platform. increased and billion continuing annually XX% lower a proper life-saving will multidrug-resistant a the awareness pathogen We has molecular auris health the and to and called of to culture. our World is and auris adoption disease to is from strengthen X U.S. detection raise professionals positive is proposition auris test and value recognized burden to estimates wait the that diseases addition public need our benefits
our over With John to to update now outlook Sprague that, fourth a for quarter I'll the detailed call our provide turn of financial financial results XXXX. and
